- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05443581
The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease
The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease:A Randomized Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiuhua Shen, Professor
- Phone Number: +86-139-1691-0428
- Email: srachel@126.com
Study Contact Backup
- Name: Kaijie Xu, Master
- Phone Number: +86-150-2668-6958
- Email: kaijie111xu@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Recruiting
- Department of Clinical Nutrition, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Xiuhua Shen, Doctor
- Phone Number: 13916910428
- Email: srachel@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically diagnosed as fatty liver, and BMI≥24.0kg/m²;
- 18-60 years old;
- Have not received drug treatment if having hyperglycemia, hyperlipidemia and high uric acid ;
- No antibiotics in the last 1 month;
- The guardian's informed consent;
Exclusion Criteria:
- Have received drug treatment of fatty liver disease within three months;
- Patients with with liver cirrhosis, viral hepatitis and other liver diseases;
- Patients with serious heart, lung, kidney diseases and patients with cancer;
- Pregnant and nursing women;
- Other conditions that may affect the results of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
Participations in this group are required to follow a healthy vegetarian diet (avoid meat, poultry, fish, dairy) during the 24-weeks trail. Daily energy intake = BMR(basal metabolic rate) × 1.25-500kcal;BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%. |
Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
|
|
Active Comparator: Control group
Participations in this group are required to follow a healthy omnivorous diet (No restriction on food sources) during the 24-weeks trail. Daily energy intake = BMR × 1.25-500kcal;BMR = 370 + 21.6 × Lean body mass(kg) Requirements of energy supply ratio: protein 15%-20%; fat 20%-25%; carbohydrate 50%-60%. |
Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary outcome was the weight of fat mass after 24 weeks intervention.
Time Frame: 24 weeks
|
Weight loss, especially the reduction of body fat mass, is the most important treatment for the prevention and treatment of MAFLD and its complicationsIn our study, we will measure weight of fat mass using a body composition analyzer (Biospace Inbody 720, Korea) at the baseline and after 24-week intervention.
The difference in the weight of fat mass after intervention between the two groups is the primary outcome.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Results of B-ultrasonic examination and Fibroscan examination
Time Frame: 24 weeks
|
Imaging examination results are an important basis for the clinical diagnosis of NAFLD, which can show the degree of hepatic steatosis and hepatic fibrosis.
Imaging findings of MAFLD will be measured and compared at the baseline and end of our study.
|
24 weeks
|
|
The changes of serum alanine aminotransferase (ALT) at week 24 intervention from the baseline
Time Frame: 24 weeks
|
Hepatic steatosis is often accompanied by changes in hepatic enzymes.
|
24 weeks
|
|
The changes of serum aspartate aminotransferase (AST) at week 24 intervention from the baseline
Time Frame: 24 weeks
|
Hepatic steatosis is often accompanied by changes in hepatic enzymes.
|
24 weeks
|
|
24-week weight change
Time Frame: 24 weeks
|
The 24-week intervention is expected to bring weight loss.
We will compare the weight loss between the two groups
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Results of compliance survey will be collected every month.
Time Frame: 24 weeks
|
We have designed a compliance scale to evaluate the compliance , which may be important to advise the nutritionists and doctors about the prevention and treatment of MAFLD.
|
24 weeks
|
|
The difference of serum superoxide dismutase (SOD) level between two groups after 24-week intervention
Time Frame: 24 weeks
|
Cause vegetarian diet may contain more phytochemicals and less saturated fat and cholesterol due to the plant-based nature of the diet, resulting in better metabolic status and milder metabolic burden,we have presumed that the serum SOD level be different between two groups at the end of study.
|
24 weeks
|
|
The difference of metabolites of Intestinal flora between two groups after 24-week intervention.
Time Frame: 24 weeks
|
The fecal samples before and after the intervention to examine the effect of vegetarian diets on gut microbiota metabolites.
|
24 weeks
|
Collaborators and Investigators
Investigators
- Study Chair: Xiuhua Shen, Professor, Xinhua Hospital Afflicated to Shanghai Jiaotong University of Medicin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XH-22-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
Foundation for the National Institutes of HealthRecruitingLiver Fat | Cirrhosis, Liver | Liver Fibrosis | NASH | Liver Inflammation | Metabolic Associated Fatty Liver Disease | Liver Steatoses | Metabolic Associated Steatotic Liver DiseaseUnited States
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE...RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver SteatosesChina
-
Tehran University of Medical SciencesNot yet recruitingLiver Transplant; Complications | Liver Transplant Disorder | End-stage Liver DiseaseIran, Islamic Republic of
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Medical University of WarsawRecruitingEnd Stage Liver Disease | Liver Transplantation | Liver Transplant | Liver Transplant SurgeryPoland
-
Shengjing HospitalEnrolling by invitationLiver Steatosis | Liver Fibrosis | Liver Fibrosis Progression in Chronic Liver Disease | Steatotic Liver Disease | Steatotic Liver Disease of Mixed Origin (MetALD)China
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
Clinical Trials on dietary intervention
-
University of ViennaCompletedEndotoxemia | Dietary HabitsAustria
-
Brown UniversityNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Brown UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University Hospital, Strasbourg, FranceRecruitingDigestive Cancer | UndernourishedFrance
-
Josephine Ford Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of South CarolinaAcademy of Nutrition and DieteticsCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated